SCHEMBL19523247

SCHEMBL19523247

COC(=O)c1ccccc1CNC1=Nc2ccccc2NC12CCSCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ALOX5 P09917 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ NOX4 Q9NPH5 1/20 0.34
▸ SIRT1 Q96EB6 1/20 0.34
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ TRPA1 O75762 1/20 0.32
▸ HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19523285 0.90 HIF1A (0.42) HIF1AALDH1A1LMNAALOX5KDM4E
SCHEMBL19523199 0.89 HIF1A (0.41) HIF1AALDH1A1LMNAALOX5KDM4E
SCHEMBL17757366 0.89 HIF1A (0.40) HIF1AALDH1A1LMNAALOX5NOX4
SCHEMBL19523221 0.88 ADRA1D (0.36) LMNAADRA1DADRA1AADRA1BTSHR
SCHEMBL19523282 0.88 ADRA1D (0.35) LMNAADRA1DADRA1AADRA1BHPGD
SCHEMBL19523172 0.84 CA1 (0.42) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL17758055 0.84 GAA (0.40) HIF1AALDH1A1KDM4EHSD17B10ALOX15
SCHEMBL17757376 0.84 CACNA1G (0.31) —
SCHEMBL19523265 0.82 NPR1 (0.34) ALDH1A1LMNASIRT1HPGD
SCHEMBL17757085 0.82 ACAT2 (0.38) ALDH1A1LMNAKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48992-E1 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2022-03-29 — — US disclosed
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
US-10280179-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2019-05-07 — — US disclosed
US-20180065982-A1 SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2018-03-08 — — US disclosed
US-9802956-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2017-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 HIF1A 1687/4885ALDH1A1 2889/4885LMNA 2101/4885
US-10280179-B2 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 HIF1A 1258/4885ALDH1A1 3845/4885LMNA 1695/4885
US-20180065982-A1 SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH AIFM2, BAD, AIFM1 HIF1A 1205/4885ALDH1A1 3830/4885LMNA 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback